{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T16:47:30Z","timestamp":1782838050032,"version":"3.54.5"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>\n                    The combination of pharmacological modulators such as lumacaftor, tezacaftor, and elexacaftor restore CFTR activity at the plasma membrane and improve lung function in patients carrying CFTR mutations such as F508del, their effects on inflammation are less clear. This study aimed to investigate whether the inflammatory response in CF airway epithelial cells depends solely on Cl\n                    <jats:sup>\u2212<\/jats:sup>\n                    transport or also on the structural integrity of the CFTR protein. We examined the effects of several CFTR modulators and wild-type CFTR overexpression on CFTR expression, trafficking, Cl\n                    <jats:sup>\u2212<\/jats:sup>\n                    channel activity, and inflammation in human CF bronchial epithelial cells. Our results demonstrate that overexpression of wild-type CFTR fully restores Cl\n                    <jats:sup>\u2212<\/jats:sup>\n                    secretion and normalizes the inflammatory response to levels observed in non-CF cells. In contrast, pharmacological correction of CFTR-F508del leads to partial recovery of Cl\n                    <jats:sup>\u2212<\/jats:sup>\n                    transport and only limited reduction of inflammation. Structural analysis revealed that corrected CFTR-F508del fails to achieve the same conformational stability as wild-type CFTR. These findings suggest that beyond ion transport, the proper folding and structural integrity of CFTR are important for regulating inflammation, potentially through interactions with other cellular proteins involved in inflammatory pathways. This work highlights the need to develop therapeutic strategies that not only restore chloride channel function but also fully correct CFTR misfolding to better control inflammation in CF.\n                  <\/jats:p>","DOI":"10.3389\/fphar.2025.1657688","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T06:43:32Z","timestamp":1766040212000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Inflammatory response in CF airway epithelial cells: a comparative study of modulators and wild-type CFTR rescue"],"prefix":"10.3389","volume":"16","author":[{"given":"Amal","family":"Kouadri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Lyko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carine","family":"El Hajjar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Cormenier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Kevin Gemy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Alfaidy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Benharouga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"951","DOI":"10.2174\/1389450116666150302114607","article-title":"Targeting ENaC as a molecular suspect in cystic fibrosis","volume":"16","author":"Bangel-Ruland","year":"2015","journal-title":"Curr. Drug Targets"},{"key":"B2","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3390\/cimb47020119","article-title":"Unraveling the mechanism of action, binding sites, and therapeutic advances of CFTR modulators: a narrative review","volume":"47","author":"Baroni","year":"2025","journal-title":"Curr. Issues Mol. Biol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2100671","DOI":"10.1183\/13993003.00671-2021","article-title":"The rescue of F508del-CFTR by elexacaftor\/tezacaftor\/ivacaftor (Trikafta) in human airway epithelial cells is underestimated due to the presence of ivacaftor","volume":"59","author":"Becq","year":"2022","journal-title":"Eur. Respir. J."},{"key":"B4","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1083\/jcb.153.5.957","article-title":"COOH-terminal truncations promote proteasome-dependent degradation of mature cystic fibrosis transmembrane conductance regulator from Post-Golgi compartments","volume":"153","author":"Benharouga","year":"2001","journal-title":"J. Cell Biol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"3448","DOI":"10.1172\/JCI125669","article-title":"Clinically approved CFTR modulators rescue Nrf2 dysfunction in cystic fibrosis airway epithelia","volume":"129","author":"Borcherding","year":"2019","journal-title":"J. Clin. Invest"},{"key":"B6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1586\/17476348.2016.1121098","article-title":"Lumacaftor alone and combined with ivacaftor: preclinical and clinical trial experience of F508del CFTR correction","volume":"10","author":"Brewington","year":"2016","journal-title":"Expert Rev. Respir. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"5262","DOI":"10.3390\/ijms22105262","article-title":"Partial rescue of F508del-CFTR stability and trafficking defects by double corrector treatment","volume":"22","author":"Capurro","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B8","doi-asserted-by":"publisher","first-page":"246ra96","DOI":"10.1126\/scitranslmed.3008680","article-title":"Potentiator ivacaftor abrogates pharmacological correction of \u0394F508 CFTR in cystic fibrosis","volume":"6","author":"Cholon","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3389\/fcell.2020.00058","article-title":"TGF-\u03b21 augments the apical membrane abundance of lemur tyrosine kinase 2 to inhibit CFTR-mediated chloride transport in human bronchial epithelia","volume":"8","author":"Cruz","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.jcf.2020.06.002","article-title":"Cystic fibrosis drug trial design in the era of CFTR modulators associated with substantial clinical benefit: stakeholders\u2019 consensus view","volume":"19","author":"De Boeck","year":"2020","journal-title":"J. Cyst. Fibros."},{"key":"B11","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.cell.2021.11.013","article-title":"Mechanism of CFTR correction by type I folding correctors","volume":"185","author":"Fiedorczuk","year":"","journal-title":"Cell"},{"key":"B12","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.cell.2021.12.005","article-title":"Mechanistic insights into CFTR folding and correction","volume":"185","author":"Fiedorczuk","year":"","journal-title":"Cell"},{"key":"B13","doi-asserted-by":"publisher","first-page":"13729","DOI":"10.1038\/s41598-019-50066-7","article-title":"Short-term consequences of F508del-CFTR thermal instability on CFTR-dependent transepithelial currents in human airway epithelial cells","volume":"9","author":"Froux","year":"2019","journal-title":"Sci. Rep."},{"key":"B14","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1021\/acsptsci.9b00094","article-title":"Emerging cystic fibrosis transmembrane conductance regulator modulators as new drugs for cystic fibrosis: a portrait of in vitro pharmacology and clinical translation","volume":"3","author":"Ghelani","year":"2020","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"B15","doi-asserted-by":"publisher","first-page":"L347","DOI":"10.1152\/ajplung.1995.268.3.L347","article-title":"Culture and transformation of human airway epithelial cells","volume":"268","author":"Gruenert","year":"1995","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1074\/jbc.M116.749515","article-title":"Correctors and potentiators rescue function of the truncated W1282X-cystic fibrosis transmembrane conductance regulator (CFTR) translation product","volume":"292","author":"Haggie","year":"2017","journal-title":"J. Biol. Chem."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2002161","DOI":"10.1183\/13993003.02161-2020","article-title":"Ivacaftor modifies cystic fibrosis neutrophil phenotype in subjects with R117H residual function CFTR mutations","volume":"57","author":"Hardisty","year":"2021","journal-title":"Eur. Respir. J."},{"key":"B18","doi-asserted-by":"publisher","first-page":"3513","DOI":"10.3390\/ijms23073513","article-title":"The effect of CFTR modulators on airway infection in cystic fibrosis","volume":"23","author":"Harvey","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1164\/rccm.201610-2088OC","article-title":"Restoring cystic fibrosis transmembrane conductance regulator function reduces airway bacteria and inflammation in people with cystic fibrosis and chronic lung infections","volume":"195","author":"Hisert","year":"","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.jcf.2016.10.002","article-title":"Ivacaftor treatment reduces airway inflammation but can alter immune cell profiles","volume":"16","author":"Hisert","year":"","journal-title":"J. Cyst. Fibros."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1128\/IAI.00283-16","article-title":"Interleukin-17 pathophysiology and therapeutic intervention in cystic fibrosis lung infection and inflammation","volume":"84","author":"Hsu","year":"2016","journal-title":"Infect. Immun."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1126\/science.2570460","article-title":"Identification of the cystic fibrosis gene: genetic analysis","volume":"245","author":"Kerem","year":"1989","journal-title":"Science"},{"key":"B24","first-page":"1","article-title":"Enhancing the potency of F508del correction: a multi-layer combinational approach to drug discovery for cystic fibrosis","volume":"1","author":"Kirby","year":"2013","journal-title":"J. Pharmacol. Clin. Toxicol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1016\/j.jcf.2019.12.002","article-title":"CFTR: new insights into structure and function and implications for modulation by small molecules","volume":"19","author":"Kleizen","year":"2020","journal-title":"J. Cyst. Fibros."},{"key":"B26","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.jcf.2019.09.011","article-title":"Whole-blood transcriptomic responses to lumacaftor\/ivacaftor therapy in cystic fibrosis","volume":"19","author":"Kopp","year":"2020","journal-title":"J. Cyst. Fibros."},{"key":"B27","doi-asserted-by":"publisher","first-page":"329","DOI":"10.3390\/biomedicines9040329","article-title":"Copper-associated oxidative stress contributes to cellular inflammatory responses in cystic fibrosis","volume":"9","author":"Kouadri","year":"2021","journal-title":"Biomedicines"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.3390\/cells10082132","article-title":"Anti-inflammatory and anti-oxidant effect of dimethyl fumarate in cystic fibrosis bronchial epithelial cells","volume":"10","author":"Laselva","year":"2021","journal-title":"Cells"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1164\/rccm.200809-1475OC","article-title":"Airway delivery of low-dose miglustat normalizes nasal potential difference in F508del cystic fibrosis mice","volume":"179","author":"Lubamba","year":"2009","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1271117","DOI":"10.3389\/fcimb.2023.1271117","article-title":"The gut\u2013lung axis in the CFTR modulator era","volume":"13","author":"Lussac-Sorton","year":"2023","journal-title":"Front. Cell Infect. Microbiol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1136\/thorax-2024-221501","article-title":"Effect of elexacaftor\/tezacaftor\/ivacaftor on systemic inflammation in cystic fibrosis","volume":"80","author":"Maher","year":"2025","journal-title":"Thorax"},{"key":"B32","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.jcf.2015.05.002","article-title":"Targeting ion channels in cystic fibrosis","volume":"14","author":"Mall","year":"2015","journal-title":"J. Cyst. Fibros."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor\u2013tezacaftor\u2013ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1165\/rcmb.2008-0368OC","article-title":"A cystic fibrosis respiratory epithelial cell chronically treated by miglustat acquires a non\u2013cystic fibrosis-like phenotype","volume":"41","author":"Norez","year":"2009","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/nchembio.1253","article-title":"Mechanism-based corrector combination restores \u0394F508-CFTR folding and function","volume":"9","author":"Okiyoneda","year":"2013","journal-title":"Nat. Chem. Biol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"9697","DOI":"10.1021\/acs.jmedchem.5b01337","article-title":"Novel hits in the correction of \u0394F508-cystic fibrosis transmembrane conductance regulator (CFTR) protein: synthesis, pharmacological, and ADME evaluation of tetrahydropyrido[4,3-d]pyrimidines for the potential treatment of cystic fibrosis","volume":"58","author":"Pesci","year":"2015","journal-title":"J. Med. Chem."},{"key":"B37","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.jcf.2013.06.005","article-title":"Lumacaftor and ivacaftor modulate inflammatory and oxidative stress pathways in cystic fibrosis cells","volume":"13","author":"Pohl","year":"2014","journal-title":"J. Cyst. Fibros."},{"key":"B38","doi-asserted-by":"publisher","first-page":"L77","DOI":"10.1152\/ajplung.00176.2004","article-title":"TGF-\u03b21 downregulates CFTR expression and function in nasal polyps of non-CF patients","volume":"288","author":"Pruli\u00e8re-Escabasse","year":"2005","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"3384","DOI":"10.3390\/ijms25063384","article-title":"Functional consequences of CFTR interactions in cystic fibrosis","volume":"25","author":"Ramananda","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1164\/rccm.201606-1231CI","article-title":"Early lung disease in infants and preschool children with cystic fibrosis: what have we learned and what should we do about it?","volume":"195","author":"Ranganathan","year":"2017","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"e181836","DOI":"10.1172\/jci.insight.181836","article-title":"Epithelial responses to CFTR modulators are improved by inflammatory cytokines and impaired by anti-inflammatory drugs","volume":"9","author":"Rehman","year":"2024","journal-title":"JCI Insight"},{"key":"B42","doi-asserted-by":"publisher","first-page":"3260","DOI":"10.3390\/cells10113260","article-title":"Impact of airway inflammation on the efficacy of CFTR modulators","volume":"10","author":"Ribeiro","year":"2021","journal-title":"Cells"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1056\/NEJMra043184","article-title":"Cystic fibrosis","volume":"352","author":"Rowe","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"8942","DOI":"10.1074\/jbc.M008888200","article-title":"Conformational and temperature-sensitive stability defects of the \u0394F508 cystic fibrosis transmembrane conductance regulator in post-endoplasmic reticulum compartments","volume":"276","author":"Sharma","year":"2001","journal-title":"J. Biol. Chem."},{"key":"B45","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1083\/jcb.200312018","article-title":"Misfolding diverts CFTR from recycling to degradation: quality control at early endosomes","volume":"164","author":"Sharma","year":"2004","journal-title":"J. Cell Biol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.3389\/fphar.2020.01090","article-title":"CFTR modulators have pleiotropic effects on epithelial and immune signaling","volume":"11","author":"Stolarczyk","year":"2020","journal-title":"Front. Pharmacol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"8928","DOI":"10.1074\/jbc.M108769200","article-title":"Genistein restores functional interactions between \u0394F508-CFTR and ENaC in Xenopus oocytes","volume":"277","author":"Suaud","year":"2002","journal-title":"J. Biol. Chem."},{"key":"B48","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1056\/NEJMoa1709846","article-title":"Tezacaftor\u2013ivacaftor in patients with cystic fibrosis homozygous for Phe508del","volume":"377","author":"Taylor-Cousar","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.jcf.2023.01.004","article-title":"Rescue by elexacaftor\u2013tezacaftor\u2013ivacaftor of the G1244E cystic fibrosis mutation\u2019s stability and gating defects are dependent on cell background","volume":"22","author":"Tomati","year":"2023","journal-title":"J. Cyst. Fibros."},{"key":"B50","doi-asserted-by":"publisher","first-page":"3946","DOI":"10.1038\/s41467-020-17783-y","article-title":"VX-445 and VX-661 rescue F508del-CFTR but residual folding defects remain","volume":"11","author":"Veit","year":"","journal-title":"Nat. Commun."},{"key":"B51","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1038\/s41591-020-0863-0","article-title":"Structure-guided combination therapy to potently improve the function of mutant CFTRs","volume":"26","author":"Veit","year":"","journal-title":"Nat. Med."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1080\/03639045.2017.1287748","article-title":"Gene delivery to the lungs: pulmonary gene therapy for cystic fibrosis","volume":"43","author":"Villate-Beitia","year":"2017","journal-title":"Drug Dev. Ind. Pharm."},{"key":"B53","doi-asserted-by":"publisher","first-page":"L882","DOI":"10.1152\/ajplung.00285.2018","article-title":"Ivacaftor affects neutrophil oxidative responses and inflammatory signaling","volume":"315","author":"Zhang","year":"2018","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1053\/j.gastro.2017.06.023","article-title":"Correction of ductal CFTR activity rescues acinar cell and pancreatic and salivary gland functions in mouse models of autoimmune disease","volume":"153","author":"Zeng","year":"2017","journal-title":"Gastroenterology"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1657688\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T06:43:34Z","timestamp":1766040214000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1657688\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":54,"alternative-id":["10.3389\/fphar.2025.1657688"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1657688","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,18]]},"article-number":"1657688"}}